Background: C-reactive protein (CRP) pharmacodynamic (PD) models have the potential to provide adjunctive methods for predicting the individual exposure response to antimicrobial therapy. We investigated CRP PD linked to a vancomycin pharmacokinetic (PK) model using routinely collected data from noncritical care adults in secondary care.
INTRODUCTION
Vancomycin is used for surgical prophylaxis and for the treatment of established infection. 1 Vancomycin is often administered empirically if the prevalence of methicillinresistant Staphylococcus aureus infection is high. The pharmacokinetics (PK) of vancomycin is highly variable in adult populations. The attainment of pharmacodynamic (PD) targets such as the area-under-the-concentration-time curve (AUC) to the minimum inhibitory concentration (MIC) ratio is associated with improved clinical outcomes. 2 Vancomycin has a narrow therapeutic index. The use of therapeutic drug monitoring (TDM) and a range of individualized dosage strategies are required to ensure safe and effective treatment. [3] [4] [5] [6] Vancomycin displays concentration-dependent antibacterial activity. The AUC:MIC is the PD index that best links drug exposure with the antibacterial effect. Values .400 are associated with improved clinical outcomes. Higher targets may be required for severe deep infections, such as methicillin-resistant S. aureus infective endocarditis. 1, [7] [8] [9] [10] [11] [12] [13] The use of AUC:MIC to guide individualized dosing requires isolation of the invading pathogen. Dosage optimization is a recurring problem in cases where the invading pathogen is not available. 14, 15 In these cases, simple measurements of Cmin, clinical judgment, physiological parameters, and biochemical markers such as C-reactive protein (CRP) are used to assess the therapeutic response. 16 CRP is used extensively for infection diagnosis and management in clinical practice. [17] [18] [19] To date, there has been little attempt to use it as a biomarker to estimate the PD of antimicrobial agents.
Recent studies in pediatric populations have used biomarkers (eg, CRP and galactomannan) to individualize antimicrobial therapy by enabling the estimation of the AUC: EC 50 . 20, 21 The EC 50 is the estimated concentration of a drug (mg/L) that is required to induce the half maximal antimicrobial effect. The EC 50 provides an in vivo estimate of drug response 20, 21 and integrates the different aspects that govern exposure-response relationships (eg, site of infection, immune status, bacterial load, and in vitro susceptibility).
This study aimed to explore whether it is possible to estimate the relationship between drug exposure and time course of CRP using routine CRP and vancomycin TDM data from noncritical care adult patients.
MATERIALS AND METHODS

Study Design and Characteristics
Data from noncritically ill patients receiving vancomycin therapy for the treatment of infections were identified from 2 audit cycles of vancomycin therapy that occurred in Imperial College Healthcare NHS Trust. The focus of the audit was to review the current standard of vancomycin use within the hospital compared with the local antimicrobial policy. The methodology used for patient identification and data collection was identical in both audits. All patients had undergone routine TDM following local hospital guidelines (which remained stable throughout the 2 audit periods that spanned 15 months from April 2016 to June 2017) for treatment of confirmed or suspected infections with vancomycin.
Guidelines recommend measuring trough plasma vancomycin concentrations and targeting 10-15 mg/L, or 15-20 mg/L for more severe or deep-seated infections. Patient characteristics, biochemistry, microbiology data, and treatment history were extracted from electronic health records. CRP data (routinely collected by the patient's clinical team as part of the infection management and clinical care) and estimated glomerular filtration rate (calculated using modification of diet in renal disease formula) were retrieved from patient electronic records.
Clinical case histories of all patients treated with vancomycin in the period evaluated were reviewed. Patients were only included if treatment was commenced for suspected or confirmed Gram-positive pathogen(s), for which vancomycin was an appropriate agent. Patients receiving concomitant therapy with other antibacterial agents with an overlapping antimicrobial spectrum were excluded. Patients with a positive culture that was not susceptible to vancomycin (ie, Gram-negative bacteria, anaerobes, or fungi) were excluded from the analysis. Patients without TDM data or on renal replacement therapy were also excluded from the analysis. Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY).
Vancomycin Bioanalysis
Vancomycin concentrations were measured using a commercially available MULTIAGENT assay implemented on an Architect analyzer (Abbott Diagnostics, Santa Clara, CA). The lower limit of quantification was 1.1 mg/L. The linear range of the assay was 1.1-100 mg/mL.
Population Pharmacokinetic Model
All PK and PD modeling was performed using Pmetrics and ADAPT 5. 22 The fit of the model to the data was assessed in the following ways: (1) log-likelihood values, (2) assessment of coefficients of determination (r 2 ) from a linear regression of the observed-predicted data, and (3) use of the Akaike information criterion. 24 
Pharmacokinetic-Pharmacodynamic Modeling
A 2-step approach to fitting PK and PD data was used. The Bayesian posterior estimates for each individual were obtained using the 2-compartment PK model described in equations 1 and 2. Posterior Bayesian estimated values (V, Cl, Kcp, and Kpc) for individual patients were fixed as covariates within a PK-PD model made up of equations 1, 2, and 3 to describe the exposure-response dynamics of CRP. This approach was implemented given the observation of vancomycin PK variability within our population and to avoid bias in parameter estimates in the PK-PD model. The PD model chosen for use in this study was selected based on previously published work investigating the exposure-response dynamics of CRP during infection. 20, 25 dXð3Þ dt
KCRPp is the maximum rate of CRP production (mg$h/L). POPmax is the maximum value of CRP (mg/L). Within our hospital, a normal CRP is defined as ,10 mg/L. In the literature, after acute-phase stimulus, CRP can be observed to rise to greater than 500 mg/L. 26 Therefore, this was used as an upper limit for the search space used in fitting the model to the data. KCRPi is the rate of maximal CRP inhibition (mg$h/ L), H is the slope function for CRP inhibition, and EC 50 is the concentration of vancomycin (mg/L) that produces a half maximal effect on CRP reduction.
Exposure-response relationship
The Bayesian posterior estimates for each patient were used to calculate the average AUC (ie, total vancomycin AUC for the treatment course divided by the number of treatment days). Posterior estimates for individual patient's EC 50 were also obtained to calculate AUC:EC 50 . This index was then fitted to patient CRP data 96-120 hours after commencing vancomycin therapy where Gram-positive infection was microbiologically confirmed. This used an Emax sigmoidal model to identify trends in the data and describe the relationship between CRP and AUC:EC 50 . The findings from evaluating the exposure-response relationship in individuals with microbiology-confirmed infections were then compared with individuals with no microbiology who were being treated empirically but had a high suspicion of Gram-positive infection.
RESULTS
Subject Selection and Characteristics
A total of 105 noncritically ill patients receiving vancomycin were identified as potential study subjects. Twenty-nine (37%) patients were eligible for consideration of inclusion in the PK-PD analysis. Of the 76 patients excluded, 20/76 (26%) were on renal replacement therapy, 16/76 (21%) had no TDM data, 8/76 (11%) had other missing data, with the remaining 22/76 (29%) dosed for less than 72 hours or treated for Gram-negative infections/noninfectious syndromes. Vancomycin therapy was used empirically in 48/105 (46%) of patients. All patients had Gram-negative and anaerobic antimicrobial cover administered at the clinician's discretion.
For the 29 subjects included in the PK-PD analysis (Table 1) 
Pharmacokinetic-Pharmacodynamic Model
A two-compartment model was found to be the optimal model for the data. The final vancomycin model had an individual posterior observation versus predicted plot r 2 of 0.83 with a bias of 0.37 and imprecision of 0.97 ( Fig. 2A) . The CRP PD model was fitted with an individual posterior observation versus predicted plot r 2 of 0.82, a bias of 20.07, and imprecision of 1.05 (Fig. 2B) . As only individual posterior estimates were required for this study, covariate modeling was not performed. A summary of the final population PK-PD parameter estimates is outlined in Table 2 . Population estimates of vancomycin PK were similar to previously reported observations in the literature. 12 
Exposure and response
Individual cases were then assessed with Bayesian posterior estimates of individual vancomycin AUC:EC 50 fitted to a sigmoid Emax model for Gram-positive confirmed patients and the relationships to CRP values at 96-120 hours after initiation of vancomycin therapy assessed (Fig. 3) . This was repeated for those individuals treated empirically. In the microbiology-confirmed cohort, one individual was excluded because of being taken back to surgery during the first 120 hours of therapy. Two individuals from the empirically treated group were also excluded as one developed active pancreatitis during the therapy and one was taken back to theater for further surgery.
Assuming a mean MIC of 1 mg/L for S. aureus and other associated organisms treated within this study (only 4/14 microbiology specimens had individual MIC data available), the optimal target vancomycin AUC would be .400 based on previously published clinical outcome data. 1, [7] [8] [9] [10] [11] [12] [13] 
DISCUSSION
The use of vancomycin in noncritically ill adults is always challenging. There is considerable PK variability. Many patients are culture negative meaning an MIC is not available to guide individualized therapy. Therefore, clinicians are forced to use TDM targets derived from a population of patients and MICs at the breakpoint in an attempt to optimize therapy for the individual patient. These approaches are not necessarily optimal for the individual being treated and fail to consider patient-level factors that determine a response to antimicrobial therapy. In an attempt to individually estimate the clinical response to an infection and subsequent antimicrobial therapy, physicians commonly use nonspecific markers such as CRP. To date, there has been very little linkage using this inflammatory marker, and other similar routinely collected biomarkers of infection, to PK-PD parameters. 20, 21 The use of AUC:EC 50 offers a novel measure to assess individual patient's response to therapy. The EC 50 value is a measure of the in vivo potency of a drug taking into account both the host factors (such as immune response and comorbid status) and organisms factors (such as resistance to the therapy being delivered and bacterial load). When linked to the exposure of the drug in question (ie, AUC), this allows for integration of factors that affect the ultimate exposureresponse relationships. The use of MIC alone only provides information on the in vitro potency of the drug for its microbiological target. Thus, the AUC:EC 50 may augment this, acting as a more inclusive estimate of PD. This may be of benefit when MIC data are not available, which is a common scenario, especially outside of the critical care setting. 14, 15 Within this study, we have demonstrated a potential of AUC:EC 50 estimates obtained through analysis of routinely available data to be able to predict a greater response of CRP during therapy. The breakpoint was estimated based on current nonindividualized AUC:MIC estimates that would routinely be considered during empirical therapy in clinical practice (ie, target AUC:MIC of .400). In comparison with estimated AUC:MIC for individual cases within this study, using published MIC breakpoints, 28 AUC:MIC .400 did not correlate with lower CRP at 96-120 hours. This may support some of the potential benefits of using EC 50 to provide a more individualized assessment of response to therapy.
However, this study also highlights several challenges that individualized therapy using measures such as the AUC: EC 50 face in the future in adult populations. In a previous study performed by Ramos-Martin et al, 20 AUC:EC 50 values in neonates predicted the likelihood of the normalization of CRP (defined as ,10 mg/L) for infants receiving teicoplanin therapy for the treatment of coagulase-negative staphylococcus line infections. In our study population, very few subjects' CRP returned to ,10 mg/L on cessation of vancomycin therapy. This is, in part, likely to be due to local antimicrobial stewardship policies for adults in the noncritical care setting that means patients are regularly reviewed and therapy is deescalated before patient's biochemical markers have returned to normal limits (usually within 72-120 hours). 29 It also reflects the comorbid state of adult patient populations in this setting. Therefore, we chose a time point of 96-120 hours given that most individuals will be treated for at least this period with vancomycin.
Given that both AUC and EC 50 can be estimated with minimal vancomycin and CRP data, it is possible that future studies could incorporate consideration of AUC:EC 50 estimation into medication reviews. This may act as a tool to help inform the likelihood of success of continued empirical therapy when no organism has been identified, providing an individualized estimate of treatment success. A further observation from this study was that a number of individuals seemed to have vancomycin concentrations below recommended targets during therapy. On review of mean dose received by individuals within the study, the observed mean of 1000 mg/24 hours may have been lower than is often recommended. However, this is a common problem observed with vancomycin therapy in similar populations and highlights some of the challenges with conventional approaches to dosing and TDM using trough concentrations. 12, 30, 31 With the development of continuous monitoring of biomarkers and antimicrobials, and translation into closedloop control systems, the AUC:EC 50 may also provide a source for dynamic individualization of therapy given that changes in the individuals' physiological state will also be considered alongside organism response. 32, 33 Further work is required to explore newer, more specific clinical biomarkers (such as procalcitonin and CD64) that have the ability to improve population PD models for delivering individualized therapy. 18 The model described within this study serves as a framework from which PK-PD models for these biomarkers can be developed and explored.
Several other limitations with the use of this model within our population were identified during the study. Given the nature of how our data were collected, PK estimates were made using sparse data, which may have influenced our estimates of vancomycin PK parameters. In future work, use of a PK model, built with informative vancomycin PK data, may be of benefit in improving the precision of PK-PD estimates. Second, a large number of individuals identified as receiving vancomycin therapy in were excluded from the analysis as they lacked TDM data, were receiving renal replacement therapy, or received vancomycin inappropriately (in Gram-negative infections). Therefore, the small and highly selected sample of individuals included means that generalizability of our findings is difficult. This also means that certain aspects may have been underpowered to demonstrate significance statistically. We now plan to investigate whether AUC:EC 50 estimates derived from a cohort of patients undergoing rich vancomycin PK-PD analysis can enhance the predictive ability of AUC:EC 50 in this scenario. This includes exploration of whether more intensive CRP monitoring can improve the accuracy of EC 50 estimates within the PD model. Finally, as we were only able to use estimated organism MIC for most clinical isolates within this study, future work will also look to ensure that individual MIC data are available to enable a comparison of the predictive power of AUC:MIC versus AUC:EC 50 .
CONCLUSIONS
In conclusion, we have demonstrated that it is possible to link antimicrobial PK and PD with direct markers of treatment response, such as CRP, using routinely collected patient data in adult, noncritical care settings. Future work must ensure that local and national antimicrobial policies are considered when investigating and setting novel PK-PD targets within specific cohorts to ensure that these can translate into clinical practice. With larger, prospective, rich data PK-PD models, the possibility of truly individualized, precision antimicrobial therapy may become a possibility. 
